8-K: DURECT Corp Announces Positive FDA Feedback and First Quarter 2024 Financial Results

DURECT Corporation reported its first quarter 2024 financial results and announced that FDA feedback supports a single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis.

Summary

• DURECT Corporation announced its first quarter 2024 financial results, with total revenues of $1.8 million and a net loss of $7.6 million.
• The company received positive feedback from the FDA regarding its larsucosterol program for alcohol-associated hepatitis (AH), which supports a single pivotal Phase 3 trial.
• DURECT is designing the Phase 3 trial based on FDA feedback and results from the Phase 2b AHFIRM trial.
• The company will present AHFIRM data at the European Association for the Study of the Liver (EASL) Congress in June 2024.
• Cash, cash equivalents, and investments totaled $21.6 million as of March 31, 2024, compared to $29.8 million at the end of 2023.
• Debt was $14.6 million at March 31, 2024, down from $16.7 million at the end of 2023.

Sentiment

Score: 7

Explanation: The document has a positive tone due to the FDA feedback supporting a single pivotal trial and the reduced net loss, but there are still risks related to cash and future trials.

Positives

• The FDA's feedback supports a streamlined path to potential approval for larsucosterol with a single pivotal Phase 3 trial.
• The net loss decreased significantly year-over-year, from $12.0 million to $7.6 million.
• The company's debt decreased from $16.7 million to $14.6 million.
• The upcoming presentation of AHFIRM data at the EASL Congress provides an opportunity to showcase the trial's findings to the medical community.

Negatives

• Total revenues decreased from $2.1 million to $1.8 million year-over-year.
• The company still reported a net loss of $7.6 million for the quarter.
• Cash, cash equivalents, and investments decreased from $29.8 million to $21.6 million since the end of 2023.

Risks

• Future clinical trials of larsucosterol may not confirm the results from the AHFIRM trial or demonstrate safety and efficacy.
• The FDA may require additional clinical trials before approving larsucosterol.
• Innocoll may not successfully commercialize POSIMIR.
• The company faces risks related to the sufficiency of cash resources and the need for additional financing.
• DURECT's ability to continue to meet the minimum bid price for continued listing on Nasdaq is a risk.
• The company's ability to continue to operate as a going concern is a risk.

Future Outlook

DURECT plans to provide additional details on its planned Phase 3 protocol and present new analyses from AHFIRM later in the year. The company is focused on advancing larsucosterol through clinical trials and seeking regulatory approval.

Management Comments

• We are pleased that the feedback from the U.S. Food and Drug Administration (FDA) supports the advancement of larsucosterol into a single pivotal Phase 3 clinical trial which, if successful, may serve as the basis for a New Drug Application (NDA) in alcohol-associated hepatitis (AH), stated James E. Brown, D.V.M., President and CEO of DURECT.

Industry Context

The announcement is significant as there are currently no FDA-approved therapies for alcohol-associated hepatitis, and larsucosterol has the potential to address this unmet medical need. The company is also exploring larsucosterol for metabolic dysfunction-associated steatohepatitis (MASH), which is another area of high unmet need.

Comparison to Industry Standards

• DURECT's focus on epigenetic therapies, particularly larsucosterol, is a novel approach compared to traditional treatments for liver diseases.
• The company's Phase 2b AHFIRM trial results are being closely watched, as the mortality rates for AH are high, with a 26% mortality rate at 28 days, 29% at 90 days and 44% at 180 days in a retrospective analysis of 77 studies.
• The FDA's Fast Track Designation for larsucosterol highlights the urgency and potential of this treatment compared to other therapies in development.
• The company's financial results are typical for a late-stage biopharmaceutical company, with a focus on R&D spending and clinical trial progress.

Stakeholder Impact

• Shareholders may view the FDA feedback and reduced net loss positively.
• Employees may be encouraged by the progress of the larsucosterol program.
• Patients with alcohol-associated hepatitis may benefit from the potential approval of larsucosterol.
• Creditors may be concerned about the company's cash position and need for additional financing.

Next Steps

• DURECT will design the Phase 3 clinical trial for larsucosterol based on FDA feedback and AHFIRM trial results.
• The company will present AHFIRM data at the EASL Congress in June 2024.
• DURECT plans to provide additional details on the Phase 3 protocol and new analyses from AHFIRM later in the year.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, AH, FDA, Phase 3 trial, AHFIRM, epigenetic, DNMT, POSIMIR, clinical trial, biopharmaceutical